Based upon the evidence, leflunomide and consequently teriflunomide are candidates for personalized dosing for use in RA. The small unbound fraction of teriflunomide within the blood makes ...

Merck said that ARR for oral teriflunomide was lower than has been seen in other recent phase 3 trials, which made it harder for evobrutinib to show an advantage, but that will be small comfort to ...

The UK's National Institute for Clinical and Health Excellence has issued final draft guidance recommending the NHS to use Sanofi's Aubagio (teriflunomide) for adult patients with relapsing ...

[20] In a 36-week Phase II study of relapsing MS, teriflunomide-treated patients showed a statistically significant decrease in active MRI lesions, and fewer subjects receiving high-dose ...